← Back to Search

Corticosteroid

Betamethasone vs. Tapinarof for Psoriasis

Phase 2 & 3

Waitlist Available

Led By Steven R Feldman, MD, PhD

Research Sponsored by Wake Forest University Health Sciences

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Adults (age 18+) with Fitzpatrick skin type 3 or higher who have been diagnosed with ICD10 code L40.9 for psoriasis between [dates] at Atrium Health Wake Forest Baptist Medical Center.

Be older than 18 years old

Must not have

Lack of a diagnosis of psoriasis (ICD10 code L40.9) or Fitzpatrick skin type below 3.

Timeline

Screening 3 weeks

Treatment Varies

Follow Up week 4 to week 12

Awards & highlights

No Placebo-Only Group

Summary

This trial will study how two psoriasis treatments affect the post-inflammatory pigmentation of legs. Photos, scales, and patient symptoms will be used to measure outcomes.

Who is the study for?

This trial is for adults over 18 with a certain skin type (Fitzpatrick skin type 3 or higher) who have been diagnosed with psoriasis. They must be stable on other treatments like biologics for at least three months before the study starts. People without this diagnosis or those with pigmentary changes that could affect outcome assessment cannot participate.

What is being tested?

The study compares two psoriasis treatments: Betamethasone dipropionate, a strong steroid cream, and Tapinarof, which works by targeting inflammation pathways. Participants will randomly receive one treatment to see how each affects skin pigmentation after inflammation.

What are the potential side effects?

Possible side effects include changes in skin coloration, irritation at the application site such as redness, burning sensation, peeling of the skin, and dryness. The severity of these side effects will vary among individuals.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am an adult with a medium to dark skin tone, diagnosed with psoriasis.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I do not have psoriasis and my skin type is 3 or above.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ week 4 to week 12

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~week 4 to week 12

This trial's timeline: 3 weeks for screening, Varies for treatment, and week 4 to week 12 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Examine the degree of Post-inflammatory pigment alteration (PIPA) in both intervention Arms

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Active Control

Group I: Betamethasone dipropionate 0.05%Active Control1 Intervention

The betamethasone dipropionate 0.05% cream group will be treated with betamethasone dipropionate 0.05% cream once daily on both legs until clear or up to 12 weeks.

Group II: TapinarofActive Control1 Intervention

The tapinarof group will be treated with 1% tapinarof cream applied once daily to both legs until clear or up to 12 weeks.

0 / 2Eligibility criteria met